ATXI Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 1.80%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $136.64

Avenue Therapeutics Insider Trading History Chart

Avenue Therapeutics Share Price & Price History

^$2.37

▲ +0.08 (3.49%)

As of 11/8/2024 10:33 AM ET

Days: 30 | 90 | 365

Financial Prophecy

From Porter & Company | Ad

The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

Avenue Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/5/2024	Jay D Kranzler	Director	Sell	61	$2.24	$136.64	559
9/8/2023	Fortress Biotech, Inc.	Major Shareholder	Buy	5,578	$54.00	$301,212.00	13,765
9/8/2023	Lindsay A Md Rosenwald	Director	Buy	4,649	$54.00	$251,046.00	4,724

The centerpiece of Trump’s crypto’s masterplan …

From Weiss Ratings | Ad

Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin conference in Nashville … Where he told an adoring crowd that the U.S. would become … “The crypto capital of the planet and the Bitcoin superpower of the world.”

Click here to find out more about what could be Trump and JD Vance’s favorite coin.

SEC Filings (Institutional Ownership Changes) for Avenue Therapeutics (NASDAQ:ATXI)

17.34% of Avenue Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Avenue Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
10/18/2024	Moss Adams Wealth Advisors LLC	11,000	$27K	0.0%	N/A	1.169%
8/15/2024	Armistice Capital LLC	75,000	$0.26M	0.0%	N/A	7.970%
1/28/2022	National Asset Management Inc.	71,338	$65K	0.0%	-20.1%	0.376%
11/16/2021	National Asset Management Inc.	89,237	$0.13M	0.0%	-29.2%	0.531%
10/19/2021	Kestra Advisory Services LLC	22,500	$34K	0.0%	N/A	0.134%
9/17/2021	Virtu Financial LLC	26,373	$66K	0.0%	N/A	0.157%
9/3/2021	Parametric Portfolio Associates LLC	10,554	$26K	0.0%	-59.2%	0.063%
8/16/2021	Occudo Quantitative Strategies LP	14,398	$36K	0.0%	N/A	0.086%
8/13/2021	Renaissance Technologies LLC	78,314	$0.20M	0.0%	N/A	0.468%
8/13/2021	Northern Trust Corp	13,767	$35K	0.0%	-82.1%	0.082%
8/13/2021	Geode Capital Management LLC	79,556	$0.20M	0.0%	-40.0%	0.475%
8/13/2021	Vanguard Group Inc.	449,982	$1.13M	0.0%	-35.5%	2.687%
8/12/2021	XTX Topco Ltd	10,864	$27K	0.0%	N/A	0.065%
8/12/2021	Advisory Services Network LLC	35,121	$88K	0.0%	N/A	0.210%
8/12/2021	Ergoteles LLC	30,400	$76K	0.0%	N/A	0.182%
8/10/2021	National Asset Management Inc.	126,037	$0.32M	0.0%	-26.1%	0.753%
5/20/2021	Axiom Investment Management LLC	10,000	$60K	0.0%	N/A	0.060%
5/19/2021	Squarepoint Ops LLC	11,668	$71K	0.0%	N/A	0.070%
5/17/2021	Goldman Sachs Group Inc.	17,319	$0.11M	0.0%	N/A	0.103%
5/13/2021	Trexquant Investment LP	13,874	$84K	0.0%	N/A	0.083%
5/13/2021	Axiom Investment Management LLC	10,000	$60K	0.0%	N/A	0.060%
5/13/2021	Barclays PLC	5,568	$34K	0.0%	+159.0%	0.033%
5/12/2021	Northern Trust Corp	77,049	$0.47M	0.0%	-6.8%	0.460%
5/12/2021	Geode Capital Management LLC	132,594	$0.80M	0.0%	+5.9%	0.792%
2/24/2021	Virtu Financial LLC	17,469	$0.10M	0.0%	N/A	0.104%
2/19/2021	JPMorgan Chase & Co.	17,102	$0.10M	0.0%	+260.2%	0.102%
2/17/2021	Jane Street Group LLC	13,288	$79K	0.0%	N/A	0.079%
2/11/2021	Northern Trust Corp	82,691	$0.49M	0.0%	+2.1%	0.494%
2/9/2021	Wells Fargo & Company MN	16,406	$98K	0.0%	-13.2%	0.098%
2/5/2021	BlackRock Inc.	361,486	$2.15M	0.0%	+5.5%	2.158%
2/4/2021	National Asset Management Inc.	167,787	$1M	0.1%	+15.0%	1.002%
11/13/2020	Morgan Stanley	22,706	$0.25M	0.0%	+270.9%	0.136%
11/10/2020	State Street Corp	73,316	$0.79M	0.0%	+9.5%	0.438%
11/9/2020	National Asset Management Inc.	145,887	$1.58M	0.1%	+42.7%	0.871%
11/6/2020	BlackRock Inc.	342,742	$3.71M	0.0%	+7.4%	2.052%

Data available starting January 2016

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

Today's Range

Now: $2.37

$2.36

$2.37

50 Day Range

MA: $2.39

$1.98

$3.02

52 Week Range

Now: $2.37

$1.70

$26.47

Volume

734 shs

Average Volume

60,866 shs

Market Capitalization

$3.39 million

P/E Ratio

0.10

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Avenue Therapeutics?: Avenue Therapeutics' top insider shareholders include:
Fortress Biotech, Inc (Major Shareholder)
Lindsay A Md Rosenwald (Director)
Jay D Kranzler (Director)
Learn More about top insider investors at Avenue Therapeutics.
Who are the major institutional investors of Avenue Therapeutics?: Avenue Therapeutics' top institutional shareholders include:
Moss Adams Wealth Advisors LLC — 1.17%
Learn More about top institutional investors of Avenue Therapeutics stock.
Which institutional investors are buying Avenue Therapeutics stock?: During the last quarter, ATXI stock was bought by institutional investors including:
Moss Adams Wealth Advisors LLC
Within the last year, these company insiders have bought Avenue Therapeutics stock:
Fortress Biotech, Inc (Major Shareholder)
Lindsay A Md Rosenwald (Director)
Learn More investors buying Avenue Therapeutics stock.